Measurement of drug concentration and bacterial contamination after diluting morphine for intrathecal administration: an experimental study

Aart Jan W. Teunissen (ajwteunissen@yahoo.co.uk)  
Maasstad Ziekenhuis  https://orcid.org/0000-0003-1895-8703

Mark V Koning  
Ziekenhuis Rijnstate Arnhem

Elisabeth J Ruijgrok  
Erasmus MC

Willem J Liefers  
Maasstad Ziekenhuis

Bart J Bruijn  
Maasstad Ziekenhuis

Seppe A Koopman  
Maasstad Ziekenhuis

Research article

**Keywords:** Morphine, bupivacaine, anesthesia providers, concentration, High-Pressure Liquid Chromatography, dilution, contamination

**Posted Date:** March 5th, 2020

**DOI:** https://doi.org/10.21203/rs.3.rs-16054/v1

**License:** © This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License

**Version of Record:** A version of this preprint was published on September 25th, 2020. See the published version at https://doi.org/10.1186/s12871-020-01151-2.
Abstract

Background: We did this study to analyse the risks posed by manual diluted morphine solutions intended for intrathecal use. Dilution of morphine is needed to achieve low concentrations for intrathecal injection. Dilution poses the risk of dilution errors and bacterial contamination. The primary goal was to compare the concentrations of morphine and bupivacaine between four groups of syringes. The secondary goal was to investigate the difference in contamination rate between these groups. Methods: 25 experienced anaesthesia providers were asked to prepare a mixture of bupivacaine 2.0 mg/ml and morphine 60 µg/ml using 3 different methods as clean and precise as possible. The fourth method used was the aspiration of ampoules prepared by the pharmacy. The concentrations of morphine and bupivacaine were measured by High-Pressure Liquid Chromatography (HPLC). The medication was cultured for bacterial contamination. Results: Group 1 (60 µg/ml; 95% CI: 59-110 µg/ml) yielded 3 outliers above 180 µg/ml morphine concentration. Group 2 (76 µg/ml; 95% CI: 72-80 µg/ml) and 3 (69 µg/ml; 95% CI: 66-71 µg/ml) were consistently higher than the target concentration of 60 µg. The group “pharmacy” was precise and accurate (59 µg/ml; 95% CI: 59-59 µg/ml). Two groups had one contaminated sample with a spore-forming aerobic gram-positive rod. Conclusion: Manually diluted morphine is at risk for deviating concentrations, which could lead to increased side-effects. Medication produced by the hospital pharmacy was highly accurate. Furthermore, even when precautions are undertaken, contamination of the medication is a serious risk and appeared to be unrelated to the dilution process. Trial registration: Not applicable

Background

Intrathecal administration of morphine is an effective method of analgesia. A single dose of 100–300 µg produces analgesia that lasts over 24 hours.\textsuperscript{1,2} However the fear for late respiratory depression typically occurring 6–11 hours after administration\textsuperscript{3} limits the use of Intrathecal morphine. This adverse event is only described in doses > 500 µg or with concomitant administration of sedatives.\textsuperscript{4-6} Given its narrow therapeutic range, accurate dosing is paramount. Is it safe to use manually diluted morphine intrathecal?

To achieve a safe dose of intrathecal morphine, low concentrations of morphine are necessary.

However, commercially available concentrations of morphine in the Netherlands range up to 10 mg/ml or 20 mg/ml. Some health care providers use small volumes of 10 mg/ml morphine to achieve a dose of 150 µg, others dilute the morphine manually.\textsuperscript{7-9} This leaves room for error with potentially fatal outcomes as a result.

In addition, precautions should be taken to prevent a contaminated injection, since the introduction of bacteria into the cerebrospinal fluid can lead to meningitis.\textsuperscript{10} Even though the incidence of meningitis after a spinal injection is estimated to be 1:53,000, manipulations for manual dilution could contaminate the injectate and increase this incidence.\textsuperscript{11}
The objective of the current study is to measure precision and accuracy in dilution of morphine and bacterial contamination. Previous studies have investigated the dilution of morphine, but limited conclusions can be drawn due to their study design.\textsuperscript{8,9} The methodology was non-standardized\textsuperscript{8} and a limited number of subjects diluted the morphine.\textsuperscript{9} This may overestimate the accuracy of clinical practice. Moreover, bacterial contamination was not measured. In this study, various experienced anesthesia providers prepared the syringes according to three standardized methods of dilution and syringes extracted from ampoules prepared by our pharmacy. We hypothesized that the number of manoeuvres increases the risk for a dilutional error and bacterial contamination.

**Methods**

For this study, medical ethical approval was waived by the medical ethical committee of the Maasstad Hospital (Toetsingscommissie Wetenschappelijk Onderzoek Rotterdam e.o., February 5, 2018). The primary outcome was the precision and accuracy in morphine concentration within groups. The secondary outcome the difference in contamination rate between these groups.

Twenty-five experienced anesthesiologists and nurse anesthetists were asked to prepare a mixture of bupivacaine and morphine according to predefined methods (Table 1). The target concentrations were 2.0 mg/ml bupivacaine and 60 µg/ml morphine. The hospital pharmacy provided ready-to-use ampoules containing a combined solution and these were used as a control group (Pharmacy group). The ampoules were prepared under Good Manufacturing Practice (GMP) conditions by the pharmacy that is GMP certified by the Dutch Health Care Inspectorate. In short, a batch of 50 sterile ampoules were prepared. The solution was prepared in a Grade A with Grade C background aseptic cleanroom and glass ampoules were filled under nitrogen. The fluid was filtered through a 0.22 µm bacterial filter. The ampoules were sterilized in the autoclave for 15 minutes in 121 degrees Celsius. Quality control tests in a GMP accredited laboratory included sterility, fill volume, shelf-life, and concentration.
Table 1
Instructions per method.

| Group    | Preparation steps                                                                 |
|----------|------------------------------------------------------------------------------------|
| Method 1 | Draw up 1 ml of 10 mg/ml morphine, Inject in a 100 ml NaCl 0.9% container, Draw up 3 ml of this mixture in a 5 ml syringe, Add 2 ml of 5 mg/ml bupivacaine |
| Method 2 | Draw up 1 ml of 10 mg/ml morphine in a 10 ml syringe, Dilute with 9 ml NaCl 0.9% in the same syringe, Dispose of 9 ml of this mixture to achieve 1 ml of 1 mg/ml, Dilute with 9 ml NaCl 0.9% in the same syringe, Draw up 3 ml of mixture in a 5 ml syringe, Add 2 ml 5 mg/ml bupivacaine |
| Method 3 | Draw up 1 ml of 1 mg/ml morphine in a 10 ml syringe, Dilute with 9 ml NaCl 0.9% in the same syringe, Draw up 3 ml of this mixture in a 5 ml syringe, Add 2 ml of 5 mg/ml bupivacaine |
| Pharmacy | Draw up 5 ml of a ready-to-use ampoule                                               |

The participants received written and oral instructions for preparation of the syringes. It was stressed that the mixtures needed to be as clean and precise as possible. As aseptic measures, caps and blue nitrile gloves were worn by the participants. All ampoules were swiped with 70% ethanol before opening. The outside of the ampoules was not touched by the BD blunt fill needles (BD, Oxford, United Kingdom). After each diluting step, the providers were advised to use a new needle.

After each prepared syringe, the participants were advised to change into new nitrile gloves. Participants could perform their tasks at their own speed. Two syringes per method were prepared, leading to a total of 8 syringes per provider. Syringes were marked after each preparation. The participants started with method 1 then method 2 and proceeded to method 3. Pharmacy group contained syringes drawn from pharmacy prepared ampoules. Per method, one syringe was analysed for drug concentration and one for bacterial contamination. No materials were re-used for method 2, 3 and pharmacy group. For method 1, two samples were taken from the same 100 ml 0.9% NaCl-container.

After preparation, all the syringes were capped and analysed the same day in the pharmacy department for drug concentrations and bacterial contamination. The syringes were tested for concentration of morphine and bupivacaine by High-Pressure Liquid Chromatography (HPLC) at 285 nm in a 125 mm X 4 mm fluid column. Testing of the microbiological culture was done with the standardized method of the
pharmacy department by injecting the fluid through a filter and culturing for 7 days of the filter. The contaminating microbes were identified in positive cultures.

**Statistics**

A power analysis was performed with GPower 3.1. To detect a difference of 20% between the groups with an alpha of 0.05 and a beta of 0.8, 8 samples per group were necessary. To increase accuracy and correct for multiple testing, 25 samples per group were obtained.

Data is described as n (%) or as median (interquartile range). The Chi-square-test was used for original data. Kruskal-Wallis was used for the testing of continuous data. A p < 0.005 was considered appropriate and Bonferroni correction was applied when necessary. All testing was performed with SPSS 25.0 (IBM, Armonk, New York) and graphics were made by GraphPad Prism version 7.1 (GraphPad Software, San Diego, California).

**Results**

All continuous data showed a non-normal distribution (Shapiro-Wilk-test, p < 0.05). The distribution of the morphine is displayed in Fig. 1. Details of morphine and bupivacaine concentrations are presented in Table 2. Group 1 had three outliers with morphine concentrations of 189, 246 and 287 µg/ml. Morphine concentrations were most precise in the pharmacy group (59 µg/ml; 95% CI of 59–59 µg/ml) followed by group 3 (69 µg/ml; % CI of 66–71 µg), group 2 (76 µg/ml; 95% CI of 72–80 µg/ml) and finally group 1 (60 µg/ml; 95% CI of 59–110 µg/ml). Groups 2 and 3 reached higher concentrations than the pharmacy group (p = 0.000, Fig. 1).
### Table 2
Details of concentrations of morphine and bupivacaine.

|                              | Group 1    | Group 2    | Group 3    | Pharmacy |
|------------------------------|------------|------------|------------|----------|
| **Morphine concentration (µg/ml)** | 60 (59–110) | 76 (72–80) | 69 (66–71) | 59 (59–59) |
| **Bupivacaine (mg/ml)**      | 1.98 (1.73–2.06) | 2.00 (1.95–2.03) | 1.97 (1.91–2.00) | 2.54 (2.54–2.55) |
| **Morphine Out-of-range (< 80%)** | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
| **Morphine Out-of-range (> 120%)** | 7 (28%) | 18 (72%) | 3 (12%) | 0 (0%) |
| **Bupivacaine Out-of-Range (< 80%)** | 1 (4%) | 0 (0%) | 1 (4%) | 0 (0%) |
| **Bupivacaine Out-of-Range (> 120%)** | 0 (0%) | 1 (4%) | 0 (0%) | 0 (0%) |

Data presented as median (95% CI) or n (%) where appropriate.

Accuracy was calculated as the difference between the individual measurements and the target-concentration. No difference in accuracy between group 2 and 3 was detected (16 µg (10–22) [2–33] vs. 9 µg (6–15) [1–28], p = 0.329). The pharmacy group was the most accurate (p = 0.000 for all comparisons with groups 1, 2 and 3). No difference in accuracy between groups 1 and 3 was detected (2 µg (95% CI: 2–51) vs. 9 (95% CI: 7–11 µg), p = 0.645).

Bupivacaine concentrations were not different between groups 1–3 (p = 1.000 for all comparisons). Since the pharmacy group had a higher concentration, we calculated the difference between the target and the measured concentrations. Again, no difference was detected (p = 1.000 for all comparisons).

There was no relation detected between the anesthesia provider and the accuracy of the morphine concentrations (P = 0.462).

Two samples had positive cultures with spore-forming aerobic gram-positive rods (group 2 & 4) (p = 1.000). All proven contaminations were diluted or extracted by the same provider. In one sample a fiber was detected (group 2).

**Discussion**

Our results show that diluting a medicine manually is prone to deviating concentrations, even by experienced personnel. The concentrations in the group “Pharmacy” were precise and accurate. Of the manual dilution methods, the 3rd led to most accurate and precise concentrations. This means that a
lower starting concentration leads to higher precision and accuracy. Contamination occurred in groups 2 and pharmacy group.

The dilution method in group 1 resulted in three cases with concentrations which could result in respiratory depression when injected intrathecally. If five millilitres of these solutions would have been injected it would result in an injected dose of 1 to 1.5 mg intrathecally. Therefore, this method should not be used. It illustrates that this dilution process is at risk of creating dangerously high morphine concentrations. The erroneous high concentration is possibly achieved because no new extraction needle was used and by the lack of rinsing off the first extracting needle in this protocol, thereby leaving a small volume of high concentration morphine in the needle. A second explanation may be because the solution did not mix properly in the 100 ml container.

The precision of group 2 and 3 was clinically acceptable, even though the accuracy was limited. When these methods of dilution are clinically applied, one has to aim for the lower limit of the therapeutic range of intrathecal morphine to prevent an inadvertent high dose. The higher concentration is possibly caused by the excess volume of a 1.0 ml morphine ampoule, which has to be more than 1.0 ml to allow an extractable volume of 1.0 ml. We believe that methods 2 and 3 are inherently safer methods, because the needle is rinsed if no new needle is used and the solution is mixed by aspiration of 9 ml of saline. This is supported by the study of Benkhadra et al., which shows that mixing of the syringe results in a homogenous distribution of the solution. Even though this was a relatively minor effect, every cause for imprecision should be excluded.

Most remarkably, 2 groups contained a contaminated sample, despite precautions of clean preparation, such as wearing non-sterile gloves and caps and swiping the ampoule with 70% ethanol before opening. We did not instruct the participants to wear face masks, because we prepared the solutions as in daily practice. We found a high frequency of contaminations, even in experienced healthcare providers. Dilution steps did not appear to increase bacterial contamination. Given the rate of contamination, it is surprising that the incidence of bacterial meningitis after an intrathecal injection is around 1: 53,000. The contamination with the aerobic spores in this study is most likely not airborne so wearing a face mask during preparation probably wouldn't have changed the results.

Several pathways for contamination of intrathecal injection are described. One pathway consists of bacteria originating from the oropharynx of the healthcare provider falling on the sterile area and instruments. A second pathway is that contaminated particles fall in the ampoule when this is opened. The current study shows contaminated medication could be an important pathway of introducing a microorganism into the cerebrospinal fluid and our precautions fail to prevent contamination by this bacteria.

This contamination with gram-positive rods is most likely bacillus cereus which is also part of the human skin flora and commonly associated with contamination. The spores of bacillus cereus are alcohol-resistant. In healthy patients, the possibility of Bacillus Cereus infection in the central nervous system
low because of intact host resistance. In immunocompromised patients, however, Bacillus Cereus was identified as causative microorganism for meningitis leading to fatal outcomes.\textsuperscript{17,18} The inability to remove the spores with alcohol might pose a risk in these patients and disinfection procedures with the use of solutions containing chlorine or hydrogen peroxide should be considered.

Bupivacaine was added to measure control of volume. The study showed that the aspiration of 2 ml into a 5 ml syringe is accurate. Furthermore, bupivacaine has antibacterial properties, making it of interest for the measurement of contamination.\textsuperscript{19} Despite this antibacterial effect, contamination occurred in 2% of the syringes. The difference in bupivacaine concentration between group pharmacy (2.5 mg/ml) and the other groups (2.0 mg/ml) is unlikely to affect the contamination rate.\textsuperscript{20,21}

A few recommendations can be made based on this study. Firstly, prefabricated drugs should be preferred in clinical practice. If this is not available, one should dilute from the lowest possible starting concentration and mix the syringe during the process. Secondly, sterile precautions should be undertaken when medication for intrathecal use is aspirated since bacterial contamination is likely to occur as shown by Zacher et al.\textsuperscript{13} Several hospitals routinely prepare drugs with high microbiological risk, such as intrathecal administrations, in a cleanroom environment, either centrally in the hospital pharmacy or decentral in a laminar flow cabinet in close proximity to the operation theatres. Contamination occurs during diluting of drugs and or during aspiration of drugs from an ampoule. Ready to administer (RTA) drugs could be considered as intrathecal drugs. Whether this precaution lowers contamination risk should be investigated further. Thirdly, clinical studies regarding intrathecal morphine sometimes do not describe the manufacturing process\textsuperscript{22} or dilute manually\textsuperscript{23}. Manually diluted drugs could yield a variance in dose with a different effect/side effect ratio. Therefore, the manufacturing process should be described in clinical studies.

A limitation of this study is that we did not determine the species beyond the gram-stain.

Gram positive aerobe spore forming bacteria are either Bacillus Antracis or Bacillus Cereus. The first would be very unlikely. Additionally, the bupivacaine concentration in the group pharmacy differed from the other groups, although this range of bupivacaine is unlikely to affect the contamination rate of Bacillus Cereus.\textsuperscript{21} Also, the incidence of contamination was not less in the pharmacy group.

**Conclusion**

We recommend using prepared solutions from the hospital pharmacy. If these are not available, it is advised to use the lowest prepared commercially or pharmacy concentration of morphine available to start with and perform as little dilution steps as possible. Use protocols that instruct the use of a new needle in every step of the dilution process. If using a new needle is omitted by mistake a protocol should contain steps that rinse this aspiration needles. This will make the protocol inherently safe. Shake the syringes after dilution. Even when these precautions are undertaken, one should expect an unprecise concentration when the medication is manually diluted. In studies, the medication should be produced by
the pharmacy since manual dilution can cause an erroneous dose. Contamination of medication is a serious risk and precautions should be taken seriously but it appeared to be unrelated to the dilution method.

**List Of Abbreviations**

mg = milligram

µg: microgram

ml = millilitre

µm = micrometre

nm = nanometre

HPLC = High-Pressure Liquid Chromatography

CI = confidence interval

GMP = Good Manufacturing Practice

BD = Becton Dickinson

RTA = Ready to administer

**Declarations**

**Ethics Approval and Consent to Participate:** All anesthesia providers verbal approved and verbal consented to participate. For this study, medical ethical approval was waived by the medical ethical committee of the Maasstad Hospital (Toetsingscommissie Wetenschappelijk Onderzoek Rotterdam e.o., February 5, 2018)

**Consent to Publish:** Not applicable

**Availability of Data and Materials:** All data generated or analysed during this study are included in this published article [and its supplementary information files]

**Competing Interest:** none

**Funding:** Maasstad Pharmacy and Operating Room department delivered all material and time consumed by their employees. Funders didn't influence the content of the manuscript

**Authors' contributions:** All authors have read and approved the manuscript

A.T.: Initiator study, corresponding author, drafting manuscript, design of study and finalization
M.K.: Fellow initiator, drafting manuscript and statistics

E.R.: Fellow initiator study and pharmaceutical foundation and backgrounds

W.L.: Review manuscript on pharmaceutical details and necessary pharmacy information

B.B.: Inclusion, instruction and coaching of anesthesia providers during study

S.K.: Review of manuscript and co-author for scientific adequacy

Acknowledgments:

We thank the departments of anesthesiology and clinical pharmacy of the Maasstad Hospital, Rotterdam, The Netherlands for their support.

References

1. Mugabure Bujedo B. A clinical approach to neuraxial morphine for the treatment of postoperative pain. Pain Res Treat 2012; 2012: 612145

2. Koning MV, Teunissen AJW, van der Harst E, Ruijgrok EJ, Stolker RJ. Intrathecal Morphine for Laparoscopic Segmental Colonic Resection as Part of an Enhanced Recovery Protocol: A Randomized Controlled Trial. Reg Anesth Pain Med 2018; 43: 166-73

3. Ko S, Goldstein DH, VanDenKerkhof EG. Definitions of "respiratory depression" with intrathecal morphine postoperative analgesia: a review of the literature. Can J Anaesth 2003; 50: 679-88

4. Dworzak H, Fuss F, Buttner T. [Persisting respiratory depression following intrathecal administration of morphine and simultaneous sedation with midazolam]. Anaesthesist 1999; 48: 639-41

5. Gehling M, Tryba M. Risks and side-effects of intrathecal morphine combined with spinal anaesthesia: a meta-analysis. Anaesthesia 2009; 64: 643-51

6. Meylan N, Elia N, Lysakowski C, Tramer MR. Benefit and risk of intrathecal morphine without local anaesthetic in patients undergoing major surgery: meta-analysis of randomized trials. Br J Anaesth 2009; 102: 156-67

7. Toyoyama H, Mizutani K, Toyoda Y. One drop of morphine added to local anesthetics by means of a 23-gauge injection needle can relieve postoperative pain under spinal anesthesia. Anesth Analg 2000; 90: 1000

8. Baker AR, Rutherford DM, Myles PS. Accuracy of dilution of morphine for intrathecal use. Anaesth Intensive Care 2007; 35: 378-81

9. Benkhadra M, Rivory JC, Wessels C, et al. Accuracy in obtaining 100 mug from 10 mg of morphine for spinal anesthesia. J Clin Anesth 2015; 27: 638-45

10. Baer ET. Post-dural puncture bacterial meningitis. Anesthesiology 2006; 105: 381-93

11. Moen V, Dahlgren N, Irestedt L. Severe neurological complications after central neuraxial blockades in Sweden 1990-1999. Anesthesiology 2004; 101: 950-9
12. Europe Council. European Pharmacopoeia, 9th edition. Strasbourg, 2015: 2.9.17 (Dosage Forms – Parenterals.).

13. Zacher AN, Zornow MH, Evans G. Drug contamination from opening glass ampules. Anesthesiology 1991; 75: 893-5

14. Videira RL, Ruiz-Neto PP, Brandao Neto M. Post spinal meningitis and asepsis. Acta Anaesthesiol Scand 2002; 46: 639-46

15. Bottone EJ. Bacillus cereus, a volatile human pathogen. Clin Microbiol Rev 2010; 23: 382-98

16. Dolan SA, Littlehorn C, Glode MP, et al. Association of Bacillus cereus infection with contaminated alcohol prep pads. Infect Control Hosp Epidemiol 2012; 33: 666-71

17. Tusgul S, Prod'hom G, Senn L, Meuli R, Bochud PY, Giulieri SG. Bacillus cereus bacteraemia: comparison between haematologic and nonhaematologic patients. New Microbes New Infect 2017; 15: 65-71

18. Stevens MP, Elam K, Bearman G. Meningitis due to Bacillus cereus: A case report and review of the literature. Can J Infect Dis Med Microbiol 2012; 23: e16-9

19. Adler DMT, Damborg P, Verwilghen DR. The antimicrobial activity of bupivacaine, lidocaine and mepivacaine against equine pathogens: An investigation of 40 bacterial isolates. Vet J 2017; 223: 27-31

20. Sakuragi T, Ishino H, Dan K. Bactericidal activity of clinically used local anesthetics on Staphylococcus aureus. Reg Anesth 1996; 21: 239-42

21. Rosenberg PH, Renkonen OV. Antimicrobial activity of bupivacaine and morphine. Anesthesiology 1985; 62: 178-9

22. Bae J, Kim HC, Hong DM. Intrathecal Morphine following robot-assisted prostatectomy: a prospective randomised trial. 2017 Aug;31(4):565-571

23. Vasudevan A1, Snowman CE, Sundar S, Sarge TW, Hess PE. Intrathecal morphine reduces breakthrough pain during labour epidural analgesia. Br J Anaesth. 2007 Feb;98(2):241-5.

Figures
Figure 1

Morphine concentrations.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- drugconcentrationbacterialcontamination.xlsx